Patents by Inventor Louis Matty

Louis Matty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7915407
    Abstract: The present invention is concerned with a process for the preparation of the compound {3-[2(R)-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl) -morpholin-4-yl]methyl]-5-oxo-4,5-dihydro-[1,2,4]-triazol-1-yl}phosphonic acid, and pharmaceutically acceptable salts thereof. This compound is useful as a substance P (neurokinin-1) receptor antagonist. In particular, the compound is useful e.g., in the treatment of emesis and inflammatory diseases.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: March 29, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James Michael McNamara, Louis Matty, Jonathan D. Rosen
  • Publication number: 20100324287
    Abstract: The present invention is concerned with a process for the preparation of the compound {3-[2(R)-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-morpholin-4-yl]methyl]-5-oxo-4,5-dihydro-[1,2,4]-triazol-1-yl}phosphonic acid, and pharmaceutically acceptable salts thereof. This compound is useful as a substance P (neurokinin-1) receptor antagonist. In particular, the compound is useful e.g., in the treatment of emesis and inflammatory diseases.
    Type: Application
    Filed: August 25, 2010
    Publication date: December 23, 2010
    Applicant: Merck Sharp & Dohme
    Inventors: James Michael McNamara, Louis Matty, Jonathan D. Rosen
  • Patent number: 7807829
    Abstract: The present invention is concerned with a process for the preparation of the compound {3-[2(R)-[(1R)-1-[3,5-bis(tri-fluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-morpholin-4-yl]methyl]-5-oxo-4,5-dihydro-[1,2,4]-triazol-1-yl}phosphonic acid, and pharmaceutically acceptable salts thereof. This compound is useful as a substance P (neurokinin-1) receptor antagonist. In particular, the compound is useful e.g., in the treatment of emesis and inflammatory diseases.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: October 5, 2010
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Corp.
    Inventors: James Michael McNamara, Louis Matty, Jonathan D. Rosen
  • Publication number: 20070265442
    Abstract: The present invention is concerned with a process for the preparation of the compound {3-[2(R)-[(1R)-1-[3,5-bis(tri-fluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-morpholin-4-yl]methyl]-5-oxo-4,5-dihydro-[1,2,4]-triazol-1-yl}phosphonic acid, and pharmaceutically acceptable salts thereof. This compound is useful as a substance P (neurokinin-1) receptor antagonist. In particular, the compound is useful e.g., in the treatment of emesis and inflammatory diseases.
    Type: Application
    Filed: November 3, 2005
    Publication date: November 15, 2007
    Inventors: James McNamara, Louis Matty, Jonathan Rosen
  • Patent number: 6998488
    Abstract: A novel process is provided for the preparation of 4-aryl piperidines, and the useful intermediates obtained therein. These compounds are intermediates for the synthesis of melanocortin-4 receptor (MC-4R), which are useful for the treatment of disorders such as obesity, diabetes, male sexual dysfunction, and female sexual dysfunction.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: February 14, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Genevieve N. Boice, Karen M. Conrad, Edward G. Corley, Louis Matty, Jr., Jerry A. Murry, Cecile G. Savarin
  • Publication number: 20040181070
    Abstract: A novel process is provided for the preparation of 4-aryl piperidines, and the useful intermediates obtained therein. These compounds are intermediates for the synthesis of melanocortin-4 receptor (MC-4R), which are useful for the treatment of disorders such as obesity, diabetes, male sexual dysfunction, and female sexual dysfunction.
    Type: Application
    Filed: March 8, 2004
    Publication date: September 16, 2004
    Inventors: Genevieve N. Boice, Karen M. Conrad, Edward G. Corley, Louis Matty, Jerry A. Murry, Cecile G. Savarin
  • Patent number: 6384244
    Abstract: cis-aminochromanols are obtained in high yield and with high selectivity over their trans counterparts by hydrogenating the corresponding oximes in the presence of a catalyst and an acid selected from HBr, HCl, and organic sulfonic acid. The cis-aminochromanols can be employed as intermediates in the production of HIV protease inhibitors which are useful for treating HIV infection and AIDS.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: May 7, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ian Davies, Karl Hansen, Paul N. Devine, Louis Matty, Jr., Yuan Cheng, Philippe M. Rabbat
  • Publication number: 20010056193
    Abstract: cis-aminochromanols are obtained in high yield and with high selectivity over their trans counterparts by hydrogenating the corresponding oximes in the presence of a catalyst and an acid selected from HBr, HCl, and organic sulfonic acid. The cis-aminochromanols can be employed as intermediates in the production of HIV protease inhibitors which are useful for treating HIV infection and AIDS.
    Type: Application
    Filed: May 11, 2001
    Publication date: December 27, 2001
    Inventors: Ian Davies, Karl Hansen, Paul N. Devine, Louis Matty,Jr., Yuan Cheng, Philippe M. Rabbat
  • Patent number: 4263123
    Abstract: Anionic grafting of olefinic monomers onto coal substrates is disclosed. The process comprises grafting polymeric side chains onto coal by contacting coal with a covalently bonded alkyl or aryl alkali metal initiator to generate carbon-alkali metal bonds and then reacting these bonds with an olefinically unsaturated monomer for a time sufficient to produce a grafted coal product having polymeric side chains bonded to the coal. The resulting coal grafts evidence enhanced solubility in organic solvents, and liquids derived from the coal grafts evidence reduced sulfur content.
    Type: Grant
    Filed: May 1, 1978
    Date of Patent: April 21, 1981
    Assignee: Exxon Research & Engineering Co.
    Inventors: Lawrence B. Ebert, Louis Matty, Jr.